109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
度普利尤单抗改善低剂量阿布昔替尼耐药性扁平苔藓淀粉样变：两例报告
Authors Zhang W, Mao D, Zhou C, Wen G
Received 21 July 2025
Accepted for publication 4 November 2025
Published 19 November 2025 Volume 2025:18 Pages 3087—3091
DOI https://doi.org/10.2147/CCID.S555311
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. Rungsima Wanitphakdeedecha
Wenxin Zhang, Dandan Mao, Cheng Zhou, Guangdong Wen
Department of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of China
Correspondence: Cheng Zhou, Department of Dermatology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, People’s Republic of China, Email chengzhou@live.cn Guangdong Wen, Department of Dermatology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, People’s Republic of China, Email 163vip2008@163.com
Abstract: Lichen amyloidosis (LA), a form of primary localized cutaneous amyloidosis, is often refractory to conventional therapies. We report two LA patients who showed inadequate response to 100mg abrocitinib daily but achieved significant improvement with dupilumab. A 29-year-old woman and a 31-year-old man with chronic, pruritic LA lesions experienced rapid itch relief with abrocitinib but minimal skin improvement after 4– 6 months, along with adverse effects, such as diarrhea, acneiform eruptions, and herpes simplex reactivation. After switching to dupilumab, both patients maintained pruritus control and exhibited marked lesion regression, with no side effects. While abrocitinib effectively alleviated itch, dupilumab demonstrated superior lesion resolution, possibly due to its dual inhibition of IL-4 and IL-13 signaling, which may more comprehensively address the underlying inflammation in LA. This is the first report of dupilumab’s efficacy after low dose abrocitinib failure in LA, suggesting its potential as a therapeutic option for refractory cases. Further studies are needed to confirm these findings.
Keywords: lichen amyloidosis, cutaneous amyloidosis, dupilumab, JAK inhibitors, treatment
Department of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of China
Correspondence: Cheng Zhou, Department of Dermatology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, People’s Republic of China, Email chengzhou@live.cn Guangdong Wen, Department of Dermatology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Xicheng District, Beijing, 100044, People’s Republic of China, Email 163vip2008@163.com
Abstract: Lichen amyloidosis (LA), a form of primary localized cutaneous amyloidosis, is often refractory to conventional therapies. We report two LA patients who showed inadequate response to 100mg abrocitinib daily but achieved significant improvement with dupilumab. A 29-year-old woman and a 31-year-old man with chronic, pruritic LA lesions experienced rapid itch relief with abrocitinib but minimal skin improvement after 4– 6 months, along with adverse effects, such as diarrhea, acneiform eruptions, and herpes simplex reactivation. After switching to dupilumab, both patients maintained pruritus control and exhibited marked lesion regression, with no side effects. While abrocitinib effectively alleviated itch, dupilumab demonstrated superior lesion resolution, possibly due to its dual inhibition of IL-4 and IL-13 signaling, which may more comprehensively address the underlying inflammation in LA. This is the first report of dupilumab’s efficacy after low dose abrocitinib failure in LA, suggesting its potential as a therapeutic option for refractory cases. Further studies are needed to confirm these findings.
Keywords: lichen amyloidosis, cutaneous amyloidosis, dupilumab, JAK inhibitors, treatment